Celltrion Symposium: Biosimilar infliximab in rheumatology: Switching from originator to biosimilar based on clinical and pharmacoeconomic data
Supported by Celltrion

16:00 – 16:50 Industry Symposium: Biosimilar infliximab in rheumatology: Switching from originator to biosimilar based on clinical and pharmacoeconomic data
Supported by Celltrion

Chairperson Tore K. Kvien, Norway
16:00 Welcome and introduction: Biosimilar
Tore K. Kvien, 
Norway
16:10 Switching from originator to biosimilar infliximab: Clinical data in RA & Real world data
TBA
16:30 Expanding access to treatment: Pharmacoeconomic of biosimilar infliximab
TBA